Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05844046
Title Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Enrico De Toni
Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.